GT Biopharma Overview

  • Year Founded
  • 1965

Year Founded

  • Status
  • Public

  • Employees
  • 9

Employees

  • Stock Symbol
  • GTBP

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.91
  • (As of Friday Closing)

GT Biopharma General Information

Description

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Contact Information

Formerly Known As
Georgetown Translational Pharmaceuticals, Oxis International
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 505 Montgomery Street
  • 10th Floor
  • San Francisco, CA 94111
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 505 Montgomery Street
  • 10th Floor
  • San Francisco, CA 94111
  • United States
+1 (415)

GT Biopharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GT Biopharma Stock Performance

As of 20-Nov-2026, GT Biopharma’s stock price is $2.91. Its current market cap is $6.33M with 2.14M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.91 $3.18 $2.87 - $23.60 $6.33M 2.14M 77.6K $47.97

GT Biopharma Financials Summary

As of 30-Sep-2026, GT Biopharma has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 6,715 5,824 398 (5,359)
Revenue 0 0 0 0
EBITDA (16,454) (28,350) (13,564) (8,164)
Net Income (16,590) (28,354) (13,162) (7,597)
Total Assets 10,568 8,106 4,232 14,109
Total Debt 0 11 0 58
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GT Biopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GT Biopharma‘s full profile, request access.

Request a free trial

GT Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel
Drug Discovery
San Francisco, CA
9 As of 2025

Lund, Sweden
 

Princeton, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GT Biopharma Competitors (88)

One of GT Biopharma’s 88 competitors is Alligator Bioscience, a Formerly VC-backed company based in Lund, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alligator Bioscience Formerly VC-backed Lund, Sweden
Soligenix Formerly VC-backed Princeton, NJ
Blueprint Medicines Formerly VC-backed Cambridge, MA
Ionis Pharmaceuticals Corporate Backed or Acquired Carlsbad, CA
Immune-Onc Therapeutics Venture Capital-Backed Palo Alto, CA
You’re viewing 5 of 88 competitors. Get the full list »

GT Biopharma Patents

GT Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022347132-A1 B7-h3 targeting fusion proteins and methods of use thereof Pending 16-Sep-2021
CA-3231445-A1 B7-h3 targeting fusion proteins and methods of use thereof Pending 16-Sep-2021
EP-4401776-A1 B7-h3 targeting fusion proteins and methods of use thereof Pending 16-Sep-2021
EP-4401776-A4 B7-h3 targeting fusion proteins and methods of use thereof Pending 16-Sep-2021
US-20250145715-A1 B7-h3 targeting fusion proteins and methods of use thereof Pending 16-Sep-2021 C07K16/2827
To view GT Biopharma’s complete patent history, request access »

GT Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GT Biopharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GT Biopharma‘s full profile, request access.

Request a free trial

GT Biopharma Acquisitions (1)

GT Biopharma’s most recent deal was a Merger/Acquisition with Oxis International. The deal was made on 05-Sep-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Oxis International 05-Sep-2017 Merger/Acquisition Pharmaceuticals
To view GT Biopharma’s complete acquisitions history, request access »

GT Biopharma ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.46 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view GT Biopharma’s complete esg history, request access »

GT Biopharma FAQs

  • When was GT Biopharma founded?

    GT Biopharma was founded in 1965.

  • Where is GT Biopharma headquartered?

    GT Biopharma is headquartered in San Francisco, CA.

  • What is the size of GT Biopharma?

    GT Biopharma has 9 total employees.

  • What industry is GT Biopharma in?

    GT Biopharma’s primary industry is Drug Discovery.

  • Is GT Biopharma a private or public company?

    GT Biopharma is a Public company.

  • What is GT Biopharma’s stock symbol?

    The ticker symbol for GT Biopharma is GTBP.

  • What is the current stock price of GT Biopharma?

    As of 20-Nov-2026 the stock price of GT Biopharma is $2.91.

  • What is the current market cap of GT Biopharma?

    The current market capitalization of GT Biopharma is $6.33M.

  • Who are GT Biopharma’s competitors?

    Alligator Bioscience, Soligenix, Blueprint Medicines, Ionis Pharmaceuticals, and Immune-Onc Therapeutics are some of the 88 competitors of GT Biopharma.

  • What is GT Biopharma’s annual earnings per share (EPS)?

    GT Biopharma’s EPS for 12 months was $47.97.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process